About This Meeting:

Genetic medicines are paving the way for groundbreaking treatments in cardiovascular diseases (CVD). With advancements in gene therapy, RNA-based therapies, stem cell research, and gene editing, a growing number of clinical trials are underway. However, challenges remain related to delivery methods, efficacy, safety, cardiac tissue modeling, long-term and off-target effects of therapies, and ethical and regulatory considerations. 

This Keystone Symposia conference on Genetic Medicines to Treat Cardiovascular Disease will explore cutting-edge advancements in identifying new therapeutic targets, translational research, and clinical studies aimed at treating CVD, including breakthroughs in genetic therapies, lessons from preclinical and clinical trials, and the integration of AI in therapeutics advancements. The program will feature panel discussions focused on the steps leading from basic discovery to translation, commercialization, FDA approval, and navigating the venture capital landscape, as well as professional development challenges for early-career researchers. 

The meeting will bring together diverse groups of basic researchers, clinicians, and industry professionals to foster meaningful discussions of the exciting opportunities emerging from industry-academia collaborations and demonstrate the crucial role that interdisciplinary collaborations play in driving growth in this area. Co-location with the joint Keystone Symposia conferences on Precision Genome Engineering: From Laboratory to Clinic and Targeted Delivery of Nucleic Acid Medicines amplifies this impact, allowing researchers to integrate advances across genome engineering, delivery technologies, and cardiovascular therapeutics in a coordinated forum. 

This meeting uniquely positions itself as a comprehensive forum that highlights not only the latest scientific discoveries and their translational impact but also explores key challenges, offering insights into pre-clinical and clinical trial design and research strategies in emerging areas like gene therapies for cardiovascular disease and the integration of AI in therapeutics advancements. 

In the video below, Drs. Litsa G. Kranias, PhD (University of Cincinnati), Dr. Rick Dewey, MD (Saturnus Bio) and Dr. James S. Ware (Imperial College London) talk about this meeting and why you should attend:

Additionally, check out the speaker highlights: